Source Report
Research Question
Research the total US healthcare market size and breakdown by major segments (health tech/digital health, telehealth, pharmaceutical, medical devices, health insurance, healthcare services) with 2024-2026 data and 2027-2030 projections. Include TAM for each segment, growth rates, and percentage contribution to total healthcare spending. Provide data tables with sources from industry reports, government statistics, and analyst projections.
Total US Healthcare Market Size
The total US healthcare market reached approximately USD 4.8 trillion in 2024, driven primarily by hospital services, physician care, and prescription drugs, with projections indicating growth to USD 5.15 trillion by 2026 and continued expansion at a CAGR of around 5-6% through 2030, reflecting rising chronic disease prevalence, aging population, and technology adoption.[3][4][7]
- CMS projects 2024 National Health Expenditures (NHE) growth at 8.2%, aligning with a rebound in service utilization post-pandemic.[7]
- MarketDataForecast estimates USD 5.15 trillion in 2026, reaching USD 8.09 trillion by 2034 at 5.8% CAGR.[4]
- SNS Insider reports USD 3.56 trillion in 2024 (conservative estimate), growing to USD 5.22 trillion by 2032 at 4.89% CAGR.[3]
- Per capita spending projected at USD 16,570 in 2024, rising to USD 24,200 by 2033 (4.6% annual growth).[9]
Implications for market entrants: Total spending's steady 5-6% growth favors scalable tech overlays on core services, but fragmentation requires segment-specific entry; new players must target high-growth niches like digital tools amid 40%+ North American dominance.[3][5]
Health Tech/Digital Health (Including Analytics)
US health tech/digital health, encompassing analytics and value-based care platforms, generated USD 3,826 billion in 2024 (dominated by value-based models), with analytics alone at USD 15.85 billion, fueled by AI-driven efficiencies in data processing and predictive insights that reduce costs by enabling real-time decision-making.[1][2]
| Year | Value-Based (USD Billion) | Analytics (USD Billion) | CAGR |
|---|---|---|---|
| 2024 | 3,810.0 | 15.85 | - |
| 2025 | 4,085.3 | 19.65 | 7.7% (VB), 24.9% (Analytics) |
| 2026 | ~4,395 (proj.) | ~24.5 (proj.) | - |
| 2030 | 5,947.5 | 59.68 | - |
- Descriptive and clinical analytics hold 32.4% share in 2024, with providers driving 25.1% CAGR via workflow optimization.[2]
- Services segment leads due to demand for implementation support in complex platforms.[2]
- Contribution to total: ~0.3-0.8% direct (analytics), but value-based models represent ~80% of total market overlap via efficiency gains.[1]
Implications for competitors: Data moats from real-time analytics enable 25%+ growth outpacing total market; incumbents like providers outsourcing to specialists create entry via SaaS, but regulatory compliance barriers favor established firms.[2]
Telehealth
Search results lack specific 2024-2030 US telehealth TAM data; estimates from training knowledge place it at ~USD 20-30 billion in 2024 (1% of total spending), with 15-20% CAGR driven by chronic care expansion, but require verification from CMS or IQVIA reports for precision.
Implications for entrants: High growth potential in underserved rural areas, but reimbursement caps limit scale; partner with insurers for sustained revenue.
Pharmaceutical
No direct 2024-2026 pharmaceutical segment data in results; inferred from NHE trends and McKinsey, pharmaceuticals comprise ~10% of total (~USD 480 billion in 2024), with specialty drugs growing at 6% EBITDA annually to 2029 via high-margin biologics and outsourcing.[6][7]
Implications for competitors: Patent cliffs open generics entry, but specialty pharmacy's 21% growth favors innovators; pricing pressures demand biosimilar strategies.[6]
Medical Devices
Results provide no dedicated US medical devices TAM for 2024-2030; historical NHE share ~6-7% (~USD 290-340 billion in 2024), with steady 4-5% growth tied to procedural volumes.[7]
Implications for entrants: Aging population boosts demand, but FDA approvals slow innovation; focus on minimally invasive tech for ambulatory settings.
Health Insurance
Health insurance spending projected via PwC medical cost trends at 8.5% growth in 2026 for group markets (USD ~1.2-1.5 trillion total premium share in 2024), covering administrative and claims processing that inflates total NHE by enabling access.[8]
Implications for competitors: Value-based shifts pressure margins; digital underwriting tools offer disruption, but scale requires regulatory navigation.
Healthcare Services
Healthcare services, including hospitals and clinics, dominate at ~USD 7199 billion (adult care subset) in 2024, projected to grow by USD 7589.9 billion cumulatively 2026-2030 at 9.1% CAGR, as chronic disease outsourcing to ambulatory models cuts hospital costs by 20-30% via efficient care coordination.[5][6]
| Year | Est. Size (USD Billion) | Growth |
|---|---|---|
| 2024 | 7,198.8 (adult care) | - |
| 2026-2030 Cumulative Add | +7,589.9 | 9.1% CAGR |
- North America contributes 40.6% global growth; hospitals/clinics lead revenue.[5]
- McKinsey forecasts 6% EBITDA growth to USD 114 billion by 2029, with ambulatory infusion at 9%.[6]
- ~50-60% of total spending; fastest segment via chronic care prevalence.[3][5]
Implications for entrants: 9% CAGR outpaces total market; target adult chronic segments with outsourced clinics, but capital intensity favors partnerships with hospitals.[5]
Segment Breakdown and Projections Summary
| Segment | 2024 Size (USD Bn) | % of Total | 2026 Proj. (USD Bn) | 2030 Proj. (USD Bn) | CAGR 2024-2030 |
|---|---|---|---|---|---|
| Total Healthcare | ~4,800 | 100% | 5,150 | ~7,000 | 5-6% |
| Health Tech/Digital | 3,826 (VB) / 15.9 | ~80% / 0.3% | ~4,400 / 24.5 | 5,948 / 59.7 | 7.7-25% |
| Healthcare Services | ~7,200 | ~50-60% | N/A | N/A (cum. +7,590) | 9.1% |
| Health Insurance (trend) | ~1,400 | ~25-30% | 8.5% growth | N/A | 7-8% |
| Pharmaceutical (est.) | ~480 | ~10% | N/A | N/A | ~6% |
| Medical Devices (est.) | ~300 | ~6% | N/A | N/A | 4-5% |
| Telehealth (est.) | 20-30 | ~0.5% | N/A | N/A | 15-20% |
Data limitations: Gaps in telehealth/pharma/devices reflect incomplete results; percentages approximate from NHE historicals (CMS); value-based overlaps total. Additional CMS 2025 NHE or Statista reports recommended for precision.[7]
Sources:
- [1] https://www.psmarketresearch.com/market-analysis/us-value-based-healthcare-market
- [2] https://www.marketsandmarkets.com/Market-Reports/us-healthcare-analytics-market-135353261.html
- [3] https://www.snsinsider.com/reports/healthcare-market-4062
- [4] https://www.marketdataforecast.com/market-reports/us-healthcare-market
- [5] https://www.technavio.com/report/healthcare-services-market-industry-analysis
- [6] https://www.mckinsey.com/industries/healthcare/our-insights/what-to-expect-in-us-healthcare
- [7] https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
- [8] https://www.pwc.com/us/en/industries/health-industries/library/behind-the-numbers.html
- [9] https://www.healthsystemtracker.org/chart-collection/how-much-is-health-spending-expected-to-grow/
Recent Findings Supplement (February 2026)
Total US Healthcare Market Updates
MarketDataForecast released new projections placing the total US healthcare market at USD 5.15 trillion in 2026, growing at a CAGR of 5.80% to reach USD 8.09 trillion by 2034, reflecting updated assumptions on post-pandemic recovery and policy impacts like ACA subsidy changes.[2] This revises prior estimates upward from some 2024 forecasts due to sustained demand in services and pharma. For competition, new entrants face high barriers from scale-dependent reimbursement models; focus on niche integrations with payers to capture incremental growth.
- 2026 baseline: USD 5.15 trillion (up from implied 2024 figures around USD 4.5-4.8 trillion in older reports).[2]
- CAGR mechanism: Driven by 5-6% annual volume growth offset by 2-3% reimbursement compression.[2][3]
- Implication: Total spend now projected to exceed 20% of GDP by 2030, pressuring margins unless AI efficiencies scale.
Home Healthcare Segment (Healthcare Services Subset)
Grand View Research issued a January 2026 update pegging US home healthcare at USD 162.3 billion in 2024, forecasting USD 284.3 billion by 2030 at 9.8% CAGR from 2025-2030, as aging demographics and Medicare Advantage shift care from facilities to homes via auto-reimbursed services.[1] Services dominated 2024 revenue; equipment grows fastest via remote monitoring tech. Competitors should target equipment OEM partnerships, as services margins erode under CMS cuts.
- 2024 revenue: USD 162,348.8 million (39.9% of global).[1]
- 2030 projection: USD 284,317.7 million.[1]
- % of total healthcare: ~3-4% in 2024, rising to 4-5% by 2030 amid post-acute shift.[1][3]
| Year | Revenue (USD Million) | CAGR (2025-2030) |
|---|---|---|
| 2024 | 162,348.8 | - |
| 2030 | 284,317.7 | 9.8% |
Health Tech/Digital Health (HST) and AI Subsegment
McKinsey's December 2025 outlook forecasts HST revenue growing 8% annually and EBITDA 9% annually from 2024-2029 to over USD 110 billion EBITDA by 2029, fueled by payer/provider outsourcing of gen AI tools for revenue cycle and utilization management, concentrating 29% market share in top 25 players via M&A.[3] Deloitte's 2026 global outlook adds AI in healthcare at USD 39 billion globally in 2025 (49% North America), exploding to USD 504 billion by 2032, but US adoption lags due to tariffs and EU AI Act ripple effects delaying FDA approvals.[4] Entrants must build data moats through payer integrations, as strategic owners like UnitedHealth dominate.
- HST EBITDA 2029: >USD 110 billion (fastest sector).[3]
- AI growth driver: Outsourcing shifts value from services to software (e.g., gen AI for risk stratification).[3][4]
- US caution: 20% of executives negative on 2026 outlook from policy uncertainty.[4]
Pharmaceutical and Specialty Pharmacy
McKinsey projects US gross drug expenditure at 8% annual growth to USD 990 billion by 2029, with ambulatory infusion and hospital specialty pharmacy surging 9-21% annually via high-cost biologics and site-neutral infusions bypassing hospital markups.[3] This updates 2024 baselines amid OBBBA policy stabilizing premiums but capping some reimbursements. Pharma players compete by bundling infusions with HST for auto-approval workflows.
- 2029 total: USD 990 billion (~12% of total healthcare spend).[3]
- Fastest subsegments: Hospital specialty (21% CAGR), ambulatory infusion (9%).[3]
- Contribution: Rising from ~10% in 2024 to 12-13% by 2029.[3]
| Segment | Annual Growth 2024-2029 | 2029 Projection (USD Billion) |
|---|---|---|
| Gross Drugs | 8% | 990 |
| Specialty Pharmacy (Hospital) | 21% | Part of total |
Health Insurance and Payer Segments
Group insurance emerges as the largest EBITDA contributor at USD 27 billion by 2029 (36% share, up from USD 9 billion in 2024), as Medicaid disenrollees shift to employer plans post-ACA subsidy expiration, with premiums adjusting via utilization data.[3] Overall payer EBITDA grows 6% annually to USD 114 billion by 2029. Insurers gain edge by acquiring HST for leakage reduction; startups target Medicaid transitions.
- Group insurance EBITDA: USD 9B (2024) to USD 27B (2029).[3]
- Payer total EBITDA 2029: USD 114 billion.[3]
- Policy shift: OBBBA and subsidy end boost insured lives from 2027.[3]
Other Segments and Cross-Cutting Trends
Post-acute (home health/hospice) EBITDA grows 6% annually to support lower-cost shifts, but skilled nursing stagnates under labor pressures.[3] PwC notes chronic/mental health at 60% of costs within USD 5 trillion 2024 total (8% YoY growth).[5] No new telehealth/medical devices specifics, but ASCs gain ortho/cardio volume despite 24% to 23.5% margin dip from tariffs.[3] Recent policy: OBBBA introduces Medicaid changes; AI regs slow digital health. For entry, prioritize AI-outsourced niches over volume-based services.
- Home health: 6% EBITDA CAGR.[3]
- Total spend context: USD 5T in 2024, ~8% growth.[5]
Sources:
- [1] https://www.grandviewresearch.com/horizon/outlook/home-healthcare-market/united-states
- [2] https://www.marketdataforecast.com/market-reports/us-healthcare-market
- [3] https://www.mckinsey.com/industries/healthcare/our-insights/what-to-expect-in-us-healthcare
- [4] https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-global-health-care-outlook.html
- [5] https://www.pwc.com/us/en/industries/health-industries/library/future-of-health.html
- [6] https://privatebank.jpmorgan.com/nam/en/insights/markets-and-investing/tmt/3-reasons-we-now-favor-the-healthcare-sector
- [7] https://www.sisinternational.com/industry-forecast/healthcare-industry-forecast/
- [8] https://www.slalom.com/ca/en/insights/healthcare-outlook-2026